

Schistosome-induced pulmonary B cells inhibit allergic airway inflammation and display a reduced Th2-driving function

LE van der Vlugt^{a,b,1}, K Obieglo^{a,1,*}, A Ozir-Fazalalikhani^a, T Sparwasser^c, S Haeberlein^{a,d}, and HH Smits^{a,*}

^a*Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands*

^b*Department of Internal Medicine-Rheumatology, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, Michigan, USA*

^c*Institute of Infection Immunology, Twincore/Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Straße 7, 30625 Hanover, Germany*

^d*Institute for Parasitology, Justus-Liebig-University Giessen, Schubertstrasse 81, Giessen, Germany*

¹Authors contributed equally

*Corresponding author. Hermelijn H. Smits, PhD Leiden University Medical Center, Department of Parasitology, Cellular Immunology of Helminths, Albinusdreef 2, 2333 ZA Leiden, The Netherlands Tel.: +31 71 5265070

E-mail address: H.H.Smits@lumc.nl

Note: Supplementary data associated with this article

Abstract

Chronic schistosome infections protect against allergic airway inflammation (AAI) via the induction of IL-10-producing splenic regulatory B (Breg) cells. Previous experiments have demonstrated that schistosome-induced pulmonary B cells can also reduce AAI, but act independently of IL-10. We have now further characterized the phenotype and inhibitory activity of these protective pulmonary B cells. We excluded a role for regulatory T (Treg) cell induction as putative AAI-protective mechanisms. Schistosome-induced B cells showed increased CD86 expression and reduced cytokine expression in response to Toll-like receptor (TLR) ligands compared with control B cells. To investigate the consequences for T cell activation we cultured ovalbumin (OVA)-pulsed, schistosome-induced B cells with OVA-specific transgenic T cells and observed less Th2 cytokine expression and T cell proliferation compared with control conditions. This suppressive effect was preserved even under optimal T cell stimulation by anti-CD3/28. Blocking of the inhibitory cytokines IL-10 or TGF- β only marginally restored Th2 cytokine induction. These data suggest that schistosome-induced pulmonary B cells are impaired in their capacity to produce cytokines to TLR ligands and to induce Th2 cytokine responses independent of their antigen-presenting function. These findings underline the presence of distinct B cell subsets with different stimulatory or inhibitory properties even if induced by the same type of helminth.

Keywords: *Schistosoma*; Regulatory B cell; Allergic airway inflammation; Th2 response; Lung

Introduction

Chronic infections with the helminth *Schistosoma mansoni* are associated with immune hypo-responsiveness and an enhanced regulatory network (McSorley and Maizels, 2012). Regulatory B (Breg) cells, which are predominantly characterized by an enhanced production of IL-10 (Rosser and Mauri, 2015), are part of this network. Their functionality was first demonstrated in mouse models of autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), lupus and chronic colitis (Goode et al., 2014). Interestingly, helminth-induced Breg cells also can inhibit inflammation and were shown to protect against EAE, systemic fatal anaphylaxis and ovalbumin (OVA)- or house dust mite allergen (Der p1)-induced allergic airway inflammation (AAI) (Amu et al., 2010; Wilson et al., 2010; van der Vlugt et al., 2012a).

Murine Breg cells were mostly detected within splenic B cell subsets (Rosser and Mauri, 2015). Breg cells have also been found within the mesenteric lymph node (LN), highly expressing the low-affinity IgE Fc receptor CD23 during *Heligmosomoides polygyrus* infection (Wilson et al., 2010), and within the B-1a B cell compartment of the peritoneal cavity (Maseda et al., 2013). Various Breg cell-associated markers and suppressive mechanisms have been reported, however most of these studies are based on splenic populations. Apart from their capacity to produce IL-10, Breg cells have been described to induce other members of the regulatory network, e.g. regulatory T (Treg) cells (Amu et al., 2010; Carter et al., 2012; van der Vlugt et al., 2012a), thereby amplifying the protective effect. B cells expressing the membrane-bound T cell immunoglobulin and mucin domain-1 (Tim-1) were able to control auto-immune (Xiao et al., 2012) and allergic diseases (Curtiss et al., 2012). Expression of CD25 by human Breg cells correlated with their IL-10 production (Kessel et al., 2012), and in mice CD25⁺ Breg cells attenuated inflammatory bowel disease (IBD) (Sattler et al., 2014). Furthermore, B cells expressing suppressive cytokines other than IL-10 have been described. TGF- β -producing Breg cells controlled inflammation in inhalation tolerance (Singh et al., 2008) and diabetes models

(Tian et al., 2001), and IL-35-producing B cells regulated immunity during EAE and *Salmonella* infection (Shen et al., 2014; Wang et al., 2014). B cells also have the capacity to suppress T cell proliferation and cytokine production via cell-cell interactions that involve inhibitory receptors, and result in T cell hypo-responsiveness or the induction of apoptosis. Examples of such inhibitory receptors are T cell-expressed PD-1, Fas as well as CTLA-4, and their respective ligands PD ligand 1 (PD-L1), PD-L2, Fas ligand (FasL) and CD80/CD86 on antigen-presenting cells (APCs) including B cells.

Apart from their role as regulators, B cells play an important role in the induction and maintenance of Th2 immunity. B cells not only produce IgE and IgG1 antibodies, they can also directly interact with Th2 T cells and act as APCs to drive their expansion and cytokine production. Indeed, presentation of allergen by pulmonary B cells has been shown to be required for full Th2 cytokine production in AAI models using μ MT and JH^{-/-} mouse models (Lindell et al., 2008; Drake et al., 2015), and immunization experiments with the cysteine protease allergen papain suggest that B cells induce T cell/T follicular helper (Tfh) cell IL-4 production in the draining LN (Dwyer et al., 2014).

We have previously shown that *S. mansoni*-infected mice are protected against OVA-induced AAI, and that both splenic and pulmonary B cells from infected mice were able to transfer protection to OVA-sensitized mice (Smits et al., 2007; van der Vlugt et al., 2012a). Intriguingly, splenic B cells inhibited AAI via IL-10 and the induction of Treg cells, while pulmonary B cells essentially acted in an IL-10-independent manner in vivo (van der Vlugt et al., 2012a). We hypothesized that schistosome infections support the development of distinct Breg cells in the lungs. Therefore, we further explored the effector mechanism by which pulmonary B cells can protect against AAI. Here, we demonstrate that pulmonary B cells from OVA-allergic mice which were infected with schistosomes are phenotypically and functionally distinct from splenic Breg cells. They have a reduced cytokine response to Toll-like receptor (TLR) ligands and

a reduced Th2 cell priming capacity, which seems to be independent of their antigen-presentation function.

1. Materials and methods

2.1. Animals

Six week-old female C57BL/6 OlaHsd mice were purchased from Harlan Sprague Dawley Inc. (USA). Dereg (depletion of regulatory T cells) mice (Lahl et al., 2007) were kindly provided by Dr. T. Sparwasser (Twincore/Centre for Experimental and Clinical Infection Research, Germany) and bred in the animal facilities of the Leiden University Medical Center (LUMC) Leiden, The Netherlands. Mice were housed under specific-pathogen-free (SPF) conditions in the animal facilities of the LUMC. All animal studies were performed in accordance with the guidelines and protocols (DEC-11166, 12182) approved by the Ethics Committee for Animal Experimentation of the University of Leiden, The Netherlands.

2.2. Parasitic infection and AAI induction

Mice were infected percutaneously with 36-40 *S. mansoni* cercariae and kept until the chronic phase of infection (15 weeks). For AAI induction, mice were sensitized twice by i.p. injections of OVA (10 µg/mL, Worthington Biochemical Corp, USA) in Imject Alum (2 mg/ml; Pierce, USA) at weeks 13 and 14. Seven days after the last injection, mice received OVA aerosol challenges (10 mg/ml in PBS) for three consecutive days. Mice were sacrificed 24 h after the last challenge. Bronchoalveolar lavage (BAL) fluids were collected and phenotyped by flow cytometry (Smits et al., 2007; van der Vlugt et al., 2012a).

2.3. Cell purification

Perfused lungs were minced to ~1 mm pieces and digested by collagenase III (Worthington) and DNase (Sigma-Aldrich, USA) for 1 h. The digested lungs were sequentially

dispersed through 70 μm sieves. Erythrocytes were removed from the lung single cell suspensions by lysis. Adhesive cells were removed from cell suspensions by passage over LS columns (Miltenyi Biotec, Germany). Next, B cells were purified using anti-CD19 MicroBeads (Miltenyi Biotec). Untouched splenic CD4⁺ T cells were enriched using negative selection with MicroBeads (Miltenyi Biotec) and were ~95% pure.

2.4. Adoptive transfer of isolated pulmonary B cells

Recipient mice were sensitized with two injections of OVA/Alum at day 0 and day 7, as described in Section 2.2. Ten days after the last injection, the OVA-sensitized animals received an i.v. injection of 5×10^6 CD19⁺ lung B cells from uninfected- or infected/OVA mice, or PBS as a control. DERE mice were treated with two diphtheria toxin (DT, 1 $\mu\text{g}/\text{ml}$) i.p. injections or PBS as a control, 1 day before and 2 days after the adoptive transfer of B cells in order to deplete the FoxP3⁺ Treg cells. After 2 days, mice were challenged for three consecutive days and sacrificed 24 h after the last challenge.

2.5. Phenotypic characterization

Ex vivo pulmonary B cells were characterized using CD25-FITC (clone: 3C7; BD Biosciences), Tim-1-PE (RMT1-4), B220-V510 (RA3-6B2), PD-L1-Pe-Cy7 (10F.9G2; all Biolegend, USA), B220-APC-eF780 (RA3-6B2), B220 eF450 (RA3-6B2), LAP-1-PerCP-eFluor710 (TW7-16B4), CD5-APC (53-7.3), CD23-PeCy7 (B3B4), CD86-PE-Cy5 (GL1), FasL-APC (MFL3), major histocompatibility complex Class II (MHCII)-APC-eF780 (M5/114.15.2), PD-L2 Biotin (TY25; all eBioscience, USA) combined with streptavidin-Qdot525 (Life Technologies, USA) and LIVE/DEAD fixable Violet or Aqua stain (eBioscience). For all flow cytometric measurements, Fc γ R-binding inhibitor (2.4G2) was added and fluorescence minus one (FMO) controls were used for gate setting for all surface markers and cytokines. All antibody stainings were performed as surface stainings for 30 min at 4°C.

2.6. Cytometric bead array

Cytokines were measured in BAL fluid and in cell culture supernatant of mesenteric lymph node (LN) cells (0.3×10^6 cells) restimulated for 3 days with $10 \mu\text{g/mL}$ of OVA using BD cytometric bead array Flex-set kits (BD Biosciences, USA).

2.7. In vitro B cell stimulation

Pulmonary $\text{CD}19^+$ B cells and B cell subsets (1×10^5 cells) were cultured in medium (RPMI 1640 glutamax; Invitrogen Life Technologies, USA), containing 5% heat-inactivated FBS (Greiner Bio-One, Austria), 5×10^{-5} M 2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 U/mL of penicillin and $100 \mu\text{g/mL}$ of streptomycin; Invitrogen). Cells were cultured either in the presence of schistosomal egg antigen (SEA; $20 \mu\text{g/ml}$), lipopolysaccharide (LPS; 100 ng/ml) or CpG-oligodeoxynucleotides (CpG-ODN) 1826 ($5 \mu\text{g/ml}$) for 5 days for the detection of IL-10 and IL-6 in culture supernatants by ELISA (BD Biosciences), or in the presence of LPS ($1 \mu\text{g/ml}$) and anti-CD40 (clone 1C10; $10 \mu\text{g/ml}$) or CpG-ODN 1826 ($1 \mu\text{g/mL}$) for the detection of IL-35 mRNA expression.

2.8. Immunoglobulin measurements

Total and OVA-specific IgG1, IgG2a and total IgA were measured from the first 1 ml of collected BAL fluid by ELISA (BD Biosciences).

2.9. In vitro B cell stimulation and co-culture with $\text{CD}4^+$ T cells

Pulmonary $\text{CD}19^+$ B ($1 \times 10^6/\text{ml}$) cells were loaded with $10 \mu\text{g/ml}$ of OVA₁₇ peptide (OVA₃₂₃₋₃₃₉: ISQAVHAAHAEINEAGR, kindly provided by M.G.M. Camps (Leiden University Medical Center, The Netherlands) for 1 h at 37°C , washed, and subsequently co-cultured with OT-II $\text{CD}4^+$ T cells (1×10^5 cells/well) at a 1:1 ratio in the presence or absence of anti-CD28 (1

µg/ml). Additionally, CD19⁺ B cells were co-cultured with CD4⁺ T cells at 1:1, 1:2, 1:4 ratios, in the presence of medium or anti-CD3 (1 µg/ml) plus anti-CD28 (1 µg/ml). To assess proliferation, T cells (10 x 10⁶/ml) were incubated with carboxy- fluorescein diacetate, succinimidyl ester (CFSE; 0.5 µM) for 15 min. Under some conditions, the following blocking antibodies were added to the cultures: 10 µg/ml of isotype control anti-βGal and anti-TGF-β (kindly provided by L. Boon, Bioceros, The Netherlands). T cells were incubated for 30 min at 37 °C with 10 µg/ml of anti-IL-10 receptor (kindly provided by L. Boon). After 3 days, CFSE-labelled T cell co-cultures were stained with anti-CD3-eFluor450 (17A2), CD25-PE (PC61.5), B220-eFluor780 (RA3-6B2), 7-AAD, CD4-biotin (GK1.5) (all eBioscience) with streptavidin-Qdot525 to measure proliferation of activated T cells. The proliferation index, being the total number of cell divisions divided by the number of cells that went into division, was calculated within the FlowJo proliferation platform. For cytokine analysis, the cells were restimulated with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml of ionomycin for 6 h in the presence of 10 µg/ml of Brefeldin A (all Sigma-Aldrich) for the last 4 h, followed by fixation using 1.9% paraformaldehyde (PFA), Sigma-Aldrich). Next, the cells were stained for viability (LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, ThermoFisher Scientific, USA) IL-4-PE (BVD4-1D11; BD Biosciences), CD3-eFluor710 (17A2), IFN-γ-FITC (XMG1.2), IL-17-PeCy7 (eBio17B7), IL-10-APC (JES5-16E3), IL-13-eFluor450 (eBio13A), and B220-eFluor780 (RA3-6B2; all eBioscience).

2.10. Quantitative PCR (qPCR)

Isolated pulmonary B cells were snap-frozen in liquid nitrogen, and RNA was isolated using the NucleoSpin RNA kit (Macherey-Nagel, Germany) according to the manufacturer's instructions. cDNA was synthesized and quantitative real-time PCR performed on a C1000 Thermal Cycler (BioRad, USA) using GoTaq qPCR MasterMix (Promega, USA). Transcripts were quantified using the following forward (FP) and reverse (RP) primers (Eurogentec,

Belgium): β -2-microglobulin FP: 5'-CACTGAATTCACCCCACTGA -3', β -2-microglobulin RP: 5'-TGTCTCGATCCCAGTAGACGG-3'; Ebi3 FP: 5'-CATTGCCACTTACAGGCTCG-3', Ebi3 RP: 5'-TGATGATTCGCTCAGCCACA-3'; IL-12p35 FP: 5'-GGTGAAGACGGCCAGAGAAA-3', IL-12p35 RP: 5'-GTAGCCAGGCAACTCTCGTT-3'. mRNA expression was normalized to the reference gene β -2-microglobulin, and expressed as the fold change to B cells from uninfected, non-allergic mice by using the $\Delta\Delta$ comparative threshold ($\Delta\Delta$ Ct) method.

2.11. Statistical analysis

All results were analyzed using GraphPad Prism (version 5.00/6.05 for Windows, GraphPad Software, La Jolla USA) and are expressed as mean \pm S.E.M. Statistical analysis was performed using the two-tailed unpaired or paired Student's *t*-test for comparison of two experimental groups, and One-Way ANOVA followed by Tukey's multiple comparisons test for comparisons between more than two groups. Differences between groups were considered significant at $P < 0.05$.

2. Results

3.1. Schistosome-induced pulmonary B cells do not share phenotypical characteristics of classical Breg cells

We first set out to investigate whether a specific pulmonary B cell subset or the expression of specific surface markers linked to Breg cell activity was selectively expanded during schistosome infection compared with uninfected mice. Pulmonary B cells did not contain typical Breg populations that have been described in the spleen, such as CD1d^{hi}CD5⁺, CD21^{hi}CD23^{lo} MZ or CD1d^{hi}CD21^{hi}CD23^{hi}IgM^{hi} transition type 2 MZ B cells (less than 0.5% of all pulmonary CD19⁺ B cells during infection, data not shown). Therefore, we analyzed several

other cell-surface markers as putative markers of Breg cell phenotype and activity, e.g. the membrane-bound marker LAP, as part of a latent TGF- β complex, CD25, Tim-1, CD5 and CD23 (Tian et al., 2001; Singh et al., 2008; Wilson et al., 2010; Lee et al., 2011; Curtiss et al., 2012; Xiao et al., 2012). Pulmonary B cells from chronically *S. mansoni*-infected, OVA-allergic (infected/OVA) mice which are known to be protective against AAI (van der Vlugt et al., 2012a) had a similar increase in LAP-1⁺ and CD25⁺ cell frequencies over B cells from uninfected, non-allergic mice (uninfected/PBS) as B cells from uninfected, OVA-allergic (uninfected/OVA) mice (Fig. 1A, Supplementary Fig. S1A), suggesting that TGF- β - or CD25-expressing B cells are not involved in protection against AAI. Although the fold increase in Tim-1⁺ B cell frequencies was significantly higher (Fig. 1A, Supplementary Fig. S1A) in infected/OVA compared with uninfected/OVA mice, the total percentages of Tim-1⁺ cells remained rather low (less than 7% of all pulmonary CD19⁺ B cells; Supplementary Fig. S1A). CD5 is one of the markers that defines the B-1a subclass of B cells which have been described to have regulatory properties (Maseda et al., 2013). The fold increase of CD5⁺ B cell frequencies was significantly reduced in infected/OVA compared with uninfected/OVA mice (Fig. 1A), indicating that this subclass of B cells is probably not important in mediating protection against AAI. The only marker assessed that was clearly enhanced on most pulmonary B cells in infected/OVA mice was CD23 (Fig. 1B, Supplementary Fig. S1B). As the majority of pulmonary B cells in naïve mice already express CD23, the fold increase in % CD23⁺ cells is only moderate. However, the per cell expression level of CD23 strongly increases on infected/OVA B cells compared with their uninfected/OVA counterparts. The increase in CD23 expression is not surprising as enhanced frequencies of CD23-expressing B cells were already demonstrated for schistosome infections (Black et al., 2010) and most probably reflects the general and modified type 2 inflammation present during chronic helminth infection (Fallon and Mangan, 2007). Furthermore, adoptive transfers of sorted CD23^{low/intermediate} or CD23^{hi} B cells from infected/OVA mice into OVA-sensitized mice remained inconclusive (data not shown), suggesting that the expression level of CD23 on pulmonary B

cells does not correlate with suppressive function in our system. Collectively, we found that pulmonary B cells of chronically *S. mansoni*-infected animals do not show enhanced expression of phenotypic markers characteristic to classical Breg cell subsets.

3.2. Pulmonary B cell-induced protection against AAI during schistosomiasis is independent of FoxP3⁺ Treg cells

We previously described that pulmonary B cells transfer protection to OVA-sensitized mice in an IL-10-independent manner (van der Vlugt et al., 2012b). We therefore set out to study the involvement of alternative inhibitory mechanisms. One of the major effector functions of murine Breg cells centers around the induction and/or recruitment of FoxP3⁺ Treg cells. In our previous studies, we observed that adoptive transfer of pulmonary B cells did not induce increased numbers of FoxP3⁺ Treg cells in vitro nor in vivo (van der Vlugt et al., 2012a). However, this does not exclude the possibility that, despite equal numbers, the activity of Treg cells on a per cell basis had increased. We therefore transferred pulmonary B cells to FoxP3-DTR transgenic DEREK mice, in which Treg cells can be temporarily depleted by DT injections (Fig. 2A), to investigate the contribution of Treg cell activity during pulmonary B cell-induced protection against AAI. BAL eosinophil numbers remained equally reduced in both PBS- and DT-treated DEREK mice when receiving pulmonary B cells from infected/OVA compared with uninfected/OVA mice (Fig. 2B). We also did not observe an enhanced induction of Treg cells by infected/OVA pulmonary B cells in in vitro co-cultures with naïve T cells compared with co-cultures with B cells from allergic control mice (data not shown). These data indicate that AAI is not restored when Treg cell activity is abolished, and suggests that schistosome-induced pulmonary B cells do not drive protection against AAI via enhanced Treg cell activity.

3.3. Schistosome-induced pulmonary B cells express elevated levels of CD86 ex vivo, and secrete less IL-10 after in vitro TLR ligation

T cell-derived Th2 cytokines play a dominant role in the induction and maintenance of AAI (Shum et al., 2008). We therefore aimed to investigate the role of pulmonary B cells as APCs and as modulators of effector T cell activation. Important signals that can influence T cell activation/induction of apoptosis, proliferation and cytokine production are, for example, provided by the co-stimulatory molecule CD86, antigen-presentation molecule MHCII, inhibitory receptors such as PD-L1, PD-L2, FasL or various cytokines such as IL-10 and IL-6. To investigate a putative role for those (co-)stimulatory molecules and/or inhibitory receptors on schistosome-induced pulmonary B cells, we first analyzed the expression of the above-mentioned molecules. Pulmonary B cells from infected/OVA mice showed a significantly increased CD86 expression compared with B cells from uninfected/OVA mice. Expression levels of MHCII, PD-L1 and PD-L2 were equal between the groups (Fig. 3A, Supplementary Fig. S2). FasL expression was not induced on pulmonary B cells in response to AAI or *S. mansoni* infection (data not shown). Furthermore, we analyzed the capacity of pulmonary B cells to produce cytokines, which may support or suppress T cell activation, following stimulation by either SEA or TLR-4 ligand LPS and TLR-9 ligand CpG-ODN 1826 as strong B-cell activators. While B cells from infected/OVA mice produced more IL-10 in response to SEA as previously described (van der Vlugt et al., 2012a), they interestingly secreted significantly less IL-10 and IL-6 in response to LPS or CpG-ODN 1826 compared with B cells from uninfected/OVA mice (Fig. 3B). Recently, B cells have been reported to secrete the regulatory cytokine IL-35 in response to TLR4 and CD40 ligation (Shen et al., 2014). Pulmonary B cells in this study were MACS-sorted for CD19, but they nevertheless contained CD138-expressing plasma cells (Supplementary Figs. S3A, B), which downregulate CD19 expression and have been described as the main IL-35 expressing B cells. We measured a clear gene expression of the IL-35 subunits *Ebi3* and *IL-12p35* by qPCR after stimulation of pulmonary B cells with LPS/anti-CD40 or CpG-ODN 1826 (Ct-values: 22-25 for *Ebi3* and *IL-12p35* after LPS/aCD40 and *IL-12p35* after CpG-ODN 1826 stimulation; 27-29 for *Ebi3* after CpG-ODN 1826 stimulation), stimuli that were reported to optimally enhance the

expression of the separate IL-35 subunits. However, we did not observe an increased expression of either IL-35 subunit by infected/OVA compared with uninfected/OVA pulmonary B cells (Supplementary Fig. S3C), suggesting that it is not likely that IL-35 mediates protection in our model. Taken together, these data show that during chronic schistosomiasis pulmonary B cells have an increased CD86 expression, equal expression levels of MHCII, lower IL-10 and IL-6 production upon TLR ligation and no increase in gene expression of the subunits for IL-35, suggesting that pulmonary B cells do not suppress Th2 cytokine production by an increased expression of those inhibitory molecules or regulatory cytokines.

3.4. Schistosome-induced pulmonary B cells induce less Th2 cytokine secretion in vitro

Because schistosome-induced pulmonary B cells did not show the typical regulatory features of Breg cells such as Treg cell induction or increased production of regulatory cytokines, we next investigated their potential to reduce AAI through a reduced APC function that would lead to less T cell proliferation and/or less T cell cytokines. To this end, T-cell activation was examined under a condition where antigen-presentation by B cells was essential to drive T-cell activation. OVA-specific T-cell activation of CD4⁺ T cells from OT-II mice was achieved by culture with OVA peptide-pulsed pulmonary B cells. After 3 days, OVA-presentation by B cells from uninfected- or infected/OVA mice did not affect intracellular expression of T-cell IL-4, IL-13 or IL-17 production, whereas IFN- γ seemed to be slightly up- and IL-10 downregulated (Fig. 4A, Supplementary Fig. S4A). We also cultured OVA-pulsed B cells and OT-II T cells in the presence of anti-CD28 to bypass differences in CD80 and CD86, and ensure optimal co-stimulation. In the presence of anti-CD28, the fold change expression of the Th2 cytokines IL-4 and IL-13 was significantly lower in co-cultures with infected/OVA B cells compared with co-cultures with B cells from uninfected/OVA mice (Fig. 4A, Supplementary Fig. S4A). The reduced IL-10 production found under stimulation conditions of infected/OVA B cell co-cultures was

overcome in the presence of sufficient co-stimulation and may point to an impaired expression during sub-optimal stimulation.

Additionally, we performed co-culture experiments of pulmonary B cells from uninfected/OVA and infected/OVA mice with CD4⁺ T cells from naive C57BL/6 mice in the presence of anti-CD3/28 to bypass the need for B cell antigen presentation and co-stimulation for T cell activation, and cultured them for 3 days. We still observed higher Th2 cytokine production in co-cultures with B cells from uninfected/OVA mice (Fig. 4D, Supplementary Fig. S4B), together with slightly more T-cell proliferation (Fig. 4B) and an enhanced T-cell CD25 expression (Fig. 4C) compared with co-cultures with infected/OVA B cells. The ability of B cells from uninfected/OVA mice to induce Th2 cytokines was found to be dose-dependent and most effective at a 1:1 ratio (Fig. 4E), while the percentage of Th2 cytokine-producing T cells induced by infected/OVA B cells was similarly low at all indicated ratios. To evaluate whether B cells could also inhibit Th2 cytokines in vivo, we turned to our previous studies, where adoptive transfer of pulmonary B cells from *S. mansoni*-infected, but not uninfected, mice protected recipient mice from AAI (van der Vlugt et al., 2012b). We now analyzed the abundance of Th2 cytokines in both the BAL fluid and mediastinal LN cell cultures of recipient mice after OVA restimulation. While the transfer of uninfected/OVA B cells strongly increased the concentration of Th2 cytokines in the BAL fluid compared with control mice (Fig. 4F), we found both IL-5 and IL-13 to be significantly reduced in both tissues after transfer of infected/OVA B cells compared with cells transferred from uninfected mice (Fig. 4F, G). Collectively, we found a lesser induction of Th2 cell proliferation and cytokine production by infected/OVA B cells, which is also evident in a setting independent of B cell antigen-presentation and with optimal co-stimulation. These findings suggest that schistosome-induced pulmonary B cells may not dampen CD4 T cell responses via a reduced APC function, but that this may be the result of both reduced Th2-driving signals and alternative inhibitory factors.

3.5. *The impaired capacity of schistosome-induced pulmonary B cells to induce Th2 cytokine secretion is largely independent of IL-10 and TGF- β*

We next aimed to investigate what other suppressive factors were involved in the reduced Th2 cell driving capacity of schistosome-induced pulmonary B cells. In that context, the roles of IL-10 and TGF- β were investigated by adding anti-IL-10R or anti-TGF β blocking antibodies to the co-cultures of pulmonary B cells and CD4⁺ T cells. We focused on the production of IL-4 and IL-13 due to the activity of these Th2 cytokines in boosting allergic responses in the airways. Blocking IL-10 signaling or neutralizing TGF- β only slightly, but significantly, increased the IL-4 production in T cells cultured with pulmonary B cells from infected/OVA mice (Fig. 5). IL-13 production was only increased upon blocking IL-10 signaling (Fig. 5). This may suggest that of the two inhibitory cytokines, the influence of IL-10 seemed to be slightly more pronounced. Nevertheless, infected/OVA B cells still induce significantly less IL-4 and IL-13 in co-cultures where IL-10 signaling is ablated or TGF- β neutralized, suggesting that either one of these cytokines, if at all, only play a minor role.

3. Discussion

Helminths drive strong immunoregulatory processes that limit immunopathology during chronic infection, and Breg cells seem to be important players. Notably, *S. mansoni*-induced splenic and pulmonary B cells also attenuate allergic diseases such as AAI upon adoptive transfer. Splenic Breg cells mediate their suppressive effect through IL-10- and Treg cell-dependent mechanisms (Amu et al., 2010; Carter et al., 2012; van der Vlugt et al., 2012a). Here, we demonstrate that helminth-induced pulmonary B cells are phenotypically and functionally distinct from splenic Breg cells that we previously studied (van der Vlugt et al., 2012a), by showing a reduced capacity to initiate Th2 cytokine responses. The question remains whether this is truly the result of an increased inhibitory, or simply a reduced Th2 stimulatory, activity.

By definition, Breg cells suppress inflammatory processes and induce tolerance by various mechanisms of which production of immunosuppressive IL-10 is the most widely studied. While IL-10 has a pleiotropic suppressive effect on most hematopoietic cells such as T cells and APCs, it also indirectly suppresses immune responses via supporting the generation and maintenance of Treg cell subsets (Amu et al., 2010; Carter et al., 2012; van der Vlugt et al., 2012a). We adoptively transferred pulmonary B cells from uninfected/OVA and infected/OVA mice into DEREK recipient mice and did not observe a significant change in the protective effect of B cells from infected mice in the absence of Treg cells (Fig. 2). We have not formally addressed where these adoptively transferred B cells migrate to in recipient mice. However, we have previously examined that i.v. injected splenic B cells migrate to the spleen and lung of allergic mice, and assume that the pulmonary B cells studied here also migrate, at least in part, to the lung (unpublished findings). Nevertheless, we cannot exclude that systemic signals have also contributed to the observed protective effect.

Recently, it has become evident that Breg cells utilize a number of IL-10-independent suppressive mechanisms in order to control inflammation (Ray et al., 2015). For example, B cells can contribute to the maintenance of tolerance via the production of TGF- β (Tian et al., 2001; Singh et al., 2008), IL-35 (Shen et al., 2014; Wang et al., 2014) or by induction of T cell hypo-responsiveness (Tian et al., 2001). The schistosome-induced pulmonary B cells studied here did not utilize any of the Breg effector mechanisms described in the above-mentioned studies. In our study, the majority of the B cells in the lungs of infected/OVA mice had elevated levels of CD23 (Fig. 1B) compared with uninfected/OVA mice. Interestingly, mesenteric LN CD23^{hi} B cells from *H. polygyrus*-infected mice were shown to suppress Der p1-induced airway inflammation by an unknown mechanism, but independently of IL-10 (Wilson et al., 2010). Although it was unclear whether this suppression was accomplished through CD23, it may point to similarities with the pulmonary B cells in the infected/OVA mice described here. As several adoptive transfer experiments with sorted pulmonary CD23⁺ B cells, compared with CD23^{low/int} B cells from

OVA/infected mice, did not show clear differences in their protection against AAI, the elevated expression of CD23 may merely serve as a proxy for a certain inhibitory phenotype without being actively involved. Alternatively, CD23 expression may not define a specific Breg population but may be more the consequence of the local cytokine milieu (Conrad, 1990), as IL-4 and IgE drive CD23 expression (Kisselgof and Oettgen, 1998; Sukumar et al., 2006) on B cells during helminth infections (Hagel et al., 1993). Indeed, the CD23 expression seemed to be elevated on almost all pulmonary B cells of infected/OVA mice. Interestingly, we found elevated concentrations of total IgG1 and IgG2a in infected/OVA compared with uninfected/OVA mice (data not shown). Earlier studies have suggested an inhibitory role for IgG1 ligating the inhibitory Fc γ RIIB in OVA-induced AAI (Ishikawa et al., 2011). However, adoptive transfers of pulmonary B cells from uninfected- and infected/OVA mice into OVA-sensitized Fc γ RIIB^{-/-} mice suggested that pulmonary B cell-induced protection against AAI was independent of Fc γ RIIB ligation (data not shown).

Schistosome-induced pulmonary B cells expressed enhanced levels of CD86, whereas MHC Class II expression levels remained unchanged and in some experiments were even enhanced. Each of these markers has been suggested to affect T cell activation. For example, down-regulation of B cell CD80 and CD86 expression during *Brugia pahangi* larval infection restricted T cell proliferation (Gillan et al., 2005). Using B cell B7^{-/-} mice, expression of CD86 was shown to be essential for B cell-mediated recovery of EAE by induction of Treg cells and IL-10 (Mann et al., 2007). In our study, co-cultures of schistosome-induced pulmonary B cells presenting OVA to OVA-specific T cells resulted in reduced Th2 cytokine production compared with control conditions. However, since similar results were observed in co-cultures of B cells from C57BL/6 mice supplemented with anti-CD3/28 to bypass the role of B cells as APCs, this may suggest the involvement of other molecules or mechanisms.

We additionally examined different inhibitory molecules for their contribution to the protective effect observed. Studies in mice with *S. mansoni* or *Litomosoides sigmodontis*

infections showed that PD-1 and interaction with its ligands (PDL-1/2) was important for T(h2)-cell hypo-responsiveness (Smith et al., 2004; van der Werf et al., 2013), and PD-1-PD-L1/2 interactions have also been reported to be involved in regulating autoimmune and allergic Th2 responses (Carter et al., 2007; Singh et al., 2011). Other studies however suggested that Th2 hypo-responsiveness during *S. mansoni* infection was not related to PD-1-PD-L1/2 interaction (Taylor et al., 2009). The latter is in agreement with our own data, as we observed that blocking of PD-L1 or PD-L2 expression on infected/OVA B cells did not restore Th2 cytokine production or proliferation in co-cultures with T cells (data not shown). We also investigated a potential role for the enhanced expression of CD86 on the pulmonary B cells from infected/OVA mice. Human CD25^{hi} Breg cells have been reported to increase the expression of the inhibitory receptor CTLA-4 on FoxP3⁺ Treg cells in vitro (Kessel et al., 2012), suggesting that the interaction of B cell co-stimulatory molecules CD80/CD86 and CTLA-4 could be important in controlling inflammation. However, blocking of CTLA-4 in in vitro co-cultures did not restore Th2 cytokine production in our study (data not shown). Collectively, the pulmonary B cells studied are phenotypically and functionally different from classical Breg cells, and rather show a reduced Th2-driving capacity. It remains to be established whether this is the result of a reduced capacity to drive Th2 stimulation, or rather a suppressive signal by which schistosome-induced pulmonary B cells actively reduce Th2 polarization and inhibit AAI.

Alternatively, local Treg cells, induced during helminth infection, may influence B cell function leading to reduced B-cell activation, antibody production and the APC function of B cells via e.g. TGF- β or IL-35 (Li et al., 2006; Collison et al., 2007; Mahnke et al., 2007). Secreted helminth products from *Schistosoma* may also directly attenuate the T cell stimulatory capacity of B cells as described for DCs (Everts et al., 2010). As pulmonary B cells from infected/OVA mice produced less cytokines after stimulation with TLR ligands (Supplementary Fig. S3), the B cells might become hypo-responsive themselves in the context of chronic *S. mansoni* infection, resulting in a reduced capacity to stimulate T cells. In addition to their role as APCs and cytokine

producers, B cells have also been reported to remodel the LN architecture to facilitate DC-dependent Th2 induction and be required for the formation of a Tfh cell response in the context of nematode infections (Leon et al., 2014; Fairfax et al., 2015).

Very little is known with regard to B cell migration to the respiratory system, and the permanence of their residence in the tissue, in contrast to other mucosal sites such as the gut or the peritoneal cavity. The lung B cell population in chronically *S. mansoni*-infected mice that are subjected to AAI is likely to be heterogeneous, consisting both of resident and infiltrating cells. Further studies are needed to examine the origin and migration pattern of the protective pulmonary B cells in *S. mansoni* infection.

Recently, various Breg cell populations have been identified in peripheral blood of humans infected with schistosomiasis or other helminths (Correale et al., 2008; van der Vlugt et al., 2012a). Furthermore, in several inflammatory diseases, Breg cells were impaired in terms of their number and/or their regulatory function, i.e. in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or allergic asthma (Blair et al., 2010; van de Veen et al., 2013; van der Vlugt et al., 2014). Since most human studies are restricted to peripheral blood B cells, these results might not fully reflect the processes that occur in inflamed organs. Therefore, further studies on B cell biology and its activity in the inflamed organs are needed to better understand the importance and relative contribution of the various Breg cell subsets in peripheral blood and local tissues. Collectively, we identified that murine infection with schistosomes induces potent IL-10-producing suppressive Breg cells in the spleen (van der Vlugt et al., 2012a) and impaired Th2-driving pulmonary B cells in the inflamed tissue (this study) which both contribute to the suppression of AAI. Identifying the mechanisms that influence pulmonary B cell function and impair their capacity to induce Th2 cytokines may be an interesting novel strategy to prevent or control allergic inflammatory responses.

Acknowledgments

We thank Louis Boon for kindly providing us with isotype control, blocking IL-10R and TGF- β antibodies. We thank Łucja A. Labuda for technical assistance. This work was supported by the Lung Foundation Netherlands (LF grant 3.2.10.072) and the Netherlands Organisation for Scientific Research (ZonMW-VIDI -016.146.352).

References

- Amu, S., Saunders, S.P., Kronenberg, M., Mangan, N.E., Atzberger, A., Fallon, P.G., 2010. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. *J Allergy Clin Immunol*, 125, 1114-1124.
- Black, C.L., Muok, E.M., Mwinzi, P.N., Carter, J.M., Karanja, D.M., Secor, W.E., Colley, D.G., 2010. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with *Schistosoma mansoni*. *J Infect Dis*, 202, 399-405.
- Blair, P.A., Norena, L.Y., Flores-Borja, F., Rawlings, D.J., Isenberg, D.A., Ehrenstein, M.R., Mauri, C., 2010. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. *Immunity*, 32, 129-140.
- Carter, L.L., Leach, M.W., Azoitei, M.L., Cui, J., Pelker, J.W., Jussif, J., Benoit, S., Ireland, G., Luxenberg, D., Askew, G.R., Milarski, K.L., Groves, C., Brown, T., Carito, B.A., Percival, K., Carreno, B.M., Collins, M., Marusic, S., 2007. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. *J Neuroimmunol*, 182, 124-134.
- Carter, N.A., Rosser, E.C., Mauri, C., 2012. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. *Arthritis Res Ther*, 14, R32.
- Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., Vignali, D.A., 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature*, 450, 566-569.
- Conrad, D.H., 1990. Fc epsilon RII/CD23: the low affinity receptor for IgE. *Annu Rev Immunol*, 8, 623-645.
- Correale, J., Farez, M., Razzitte, G., 2008. Helminth infections associated with multiple sclerosis induce regulatory B cells. *Ann Neurol*, 64, 187-199.
- Curtiss, M.L., Gorman, J.V., Businga, T.R., Traver, G., Singh, M., Meyerholz, D.K., Kline, J.N., Murphy, A.J., Valenzuela, D.M., Colgan, J.D., Rothman, P.B., Cassel, S.L., 2012. Tim-1 regulates Th2 responses in an airway hypersensitivity model. *Eur J Immunol*, 42, 651-661.
- Drake, L.Y., Iijima, K., Hara, K., Kobayashi, T., Kephart, G.M., Kita, H., 2015. B cells play key roles in th2-type airway immune responses in mice exposed to natural airborne allergens. *PLoS One*, 10, e0121660.
- Dwyer, D.F., Woodruff, M.C., Carroll, M.C., Austen, K.F., Gurish, M.F., 2014. B cells regulate CD4+ T cell responses to papain following B cell receptor-independent papain uptake. *J Immunol*, 193, 529-539.
- Everts, B., Smits, H.H., Hokke, C.H., Yazdanbakhsh, M., 2010. Helminths and dendritic cells: sensing and regulating via pattern recognition receptors, Th2 and Treg responses. *Eur J Immunol*, 40, 1525-1537.
- Fairfax, K.C., Everts, B., Amiel, E., Smith, A.M., Schramm, G., Haas, H., Randolph, G.J., Taylor, J.J., Pearce, E.J., 2015. IL-4-secreting secondary T follicular helper (Tfh) cells arise from memory T cells, not persisting Tfh cells, through a B cell-dependent mechanism. *J Immunol*, 194, 2999-3010.
- Fallon, P.G., Mangan, N.E., 2007. Suppression of TH2-type allergic reactions by helminth infection. *Nature Rev Immunology*, 7, 220-230.
- Gillan, V., Lawrence, R.A., Devaney, E., 2005. B cells play a regulatory role in mice infected with the L3 of *Brugia pahangi*. *Int Immunol*, 17, 373-382.
- Goode, I., Xu, H., Ildstad, S.T., 2014. Regulatory B cells: the new "it" cell. *Transplant Proc*, 46, 3-8.

- Hagel, I., Lynch, N.R., Di Prisco, M.C., Rojas, E., Perez, M., Alvarez, N., 1993. *Ascaris* reinfection of slum children: relation with the IgE response. *Clin Exp Immunol*, 94, 80-83.
- Ishikawa, Y., Kobayashi, K., Yamamoto, M., Nakata, K., Takagawa, T., Funada, Y., Kotani, Y., Karasuyama, H., Yoshida, M., Nishimura, Y., 2011. Antigen-Specific IgG ameliorates allergic airway inflammation via Fc γ receptor IIB on dendritic cells. *Respir Res*, 12, 42.
- Kessel, A., Haj, T., Peri, R., Snir, A., Melamed, D., Sabo, E., Toubi, E., 2012. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. *Autoimmun Rev*, 11, 670-677.
- Kisselgof, A.B., Oettgen, H.C., 1998. The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE. *Int Immunol*, 10, 1377-1384.
- Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G., Hamann, A., Wagner, H., Huehn, J., Sparwasser, T., 2007. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J Exp Med*, 204, 57-63.
- Lee, J.H., Noh, J., Noh, G., Choi, W.S., Cho, S., Lee, S.S., 2011. Allergen-specific transforming growth factor-beta-producing CD19+CD5+ regulatory B-cell (Br3) responses in human late eczematous allergic reactions to cow's milk. *J Interferon Cytokine Res*, 31, 441-449.
- Leon, B., Ballesteros-Tato, A., Lund, F.E., 2014. Dendritic cells and B cells: unexpected partners in Th2 development. *J Immunol*, 193, 1531-1537.
- Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., Flavell, R.A., 2006. Transforming growth factor-beta regulation of immune responses. *Annu Rev Immunol*, 24, 99-146.
- Lindell, D.M., Berlin, A.A., Schaller, M.A., Lukacs, N.W., 2008. B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease. *PLoS One*, 3, e3129.
- Mahnke, K., Bedke, T., Enk, A.H., 2007. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. *Cell Immunol*, 250, 1-13.
- Mann, M.K., Maresz, K., Shriver, L.P., Tan, Y., Dittel, B.N., 2007. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. *J Immunol*, 178, 3447-3456.
- Maseda, D., Candando, K.M., Smith, S.H., Kalampokis, I., Weaver, C.T., Plevy, S.E., Poe, J.C., Tedder, T.F., 2013. Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-gamma+CD4+ T cell numbers during colitis development in mice. *J Immunol*, 191, 2780-2795.
- McSorley, H.J., Maizels, R.M., 2012. Helminth infections and host immune regulation. *Clin Microbiol Rev*, 25, 585-608.
- Ray, A., Wang, L., Dittel, B.N., 2015. IL-10-independent regulatory B-cell subsets and mechanisms of action. *Int Immunol* 27, 531-536.
- Rosser, E.C., Mauri, C., 2015. Regulatory B cells: origin, phenotype, and function. *Immunity* 42, 607-612.
- Sattler, S., Ling, G.S., Xu, D., Husaarts, L., Romaine, A., Zhao, H., Fossati-Jimack, L., Malik, T., Cook, H.T., Botto, M., Lau, Y.L., Smits, H.H., Liew, F.Y., Huang, F.P., 2014. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. *J Autoimmun* 50, 107-122.
- Shen, P., Roch, T., Lampropoulou, V., O'Connor, R.A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V.D., Jaimes, Y., Daridon, C., Li, R., Jouneau, L., Boudinot, P., Wilantri, S., Sakwa, I., Miyazaki, Y., Leech, M.D., McPherson, R.C., Wirtz, S., Neurath, M., Hoehlig, K., Meinel, E., Grutzkau, A., Grun, J.R., Horn, K., Kuhl, A.A., Dorner, T., Bar-Or, A., Kaufmann, S.H., Anderton, S.M., Fillatreau, S., 2014. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *Nature*, 507, 366-370.

- Shum, B.O., Rolph, M.S., Sewell, W.A., 2008. Mechanisms in allergic airway inflammation - lessons from studies in the mouse. *Expert Rev Mol Med*, 10, e15.
- Singh, A., Carson, W.F.t., Secor, E.R., Jr., Guernsey, L.A., Flavell, R.A., Clark, R.B., Thrall, R.S., Schramm, C.M., 2008. Regulatory role of B cells in a murine model of allergic airway disease. *J Immunol*, 180, 7318-7326.
- Singh, A.K., Stock, P., Akbari, O., 2011. Role of PD-L1 and PD-L2 in allergic diseases and asthma. *Allergy*, 66, 155-162.
- Smith, P., Walsh, C.M., Mangan, N.E., Fallon, R.E., Sayers, J.R., McKenzie, A.N., Fallon, P.G., 2004. *Schistosoma mansoni* worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. *J Immunol*, 173, 1240-1248.
- Smits, H.H., Hammad, H., van Nimwegen, M., Soullie, T., Willart, M.A., Lievers, E., Kadouch, J., Kool, M., Kos-van Oosterhoud, J., Deelder, A.M., Lambrecht, B.N., Yazdanbakhsh, M., 2007. Protective effect of *Schistosoma mansoni* infection on allergic airway inflammation depends on the intensity and chronicity of infection. *J Allergy Clin Immunol* 120, 932-940.
- Sukumar, S., Conrad, D.H., Szakal, A.K., Tew, J.G., 2006. Differential T cell-mediated regulation of CD23 (Fc epsilonRII) in B cells and follicular dendritic cells. *J Immunol*, 176, 4811-4817.
- Taylor, J.J., Krawczyk, C.M., Mohrs, M., Pearce, E.J., 2009. Th2 cell hyporesponsiveness during chronic murine schistosomiasis is cell intrinsic and linked to GRAIL expression. *J Clin Invest*, 119, 1019-1028.
- Tian, J., Zekzer, D., Hanssen, L., Lu, Y., Olcott, A., Kaufman, D.L., 2001. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. *J Immunol*, 167, 1081-1089.
- van de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., Sollner, S., Akdis, D.G., Ruckert, B., Akdis, C.A., Akdis, M., 2013. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. *J Allergy Clin Immunol*, 131, 1204-1212.
- van der Vlugt, L.E., Labuda, L.A., Ozir-Fazalalikhani, A., Lievers, E., Gloudemans, A.K., Liu, K.Y., Barr, T.A., Sparwasser, T., Boon, L., Ngoa, U.A., Feugap, E.N., Adegnika, A.A., Kremsner, P.G., Gray, D., Yazdanbakhsh, M., Smits, H.H., 2012a. Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. *PLoS One*, 7, e30883.
- van der Vlugt, L.E., Labuda, L.A., Ozir-Fazalalikhani, A., Lievers, E., Gloudemans, A.K., Liu, K.Y., Barr, T.A., Sparwasser, T., Boon, L., Ngoa, U.A., Feugap, E.N., Adegnika, A.A., Kremsner, P.G., Gray, D., Yazdanbakhsh, M., Smits, H.H., 2012b. Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. *PLoS One*, 7, e30883.
- van der Vlugt, L.E., Mlejnek, E., Ozir-Fazalalikhani, A., Janssen Bonas, M., Dijkman, T.R., Labuda, L.A., Schot, R., Guigas, B., Moller, G.M., Hiemstra, P.S., Yazdanbakhsh, M., Smits, H.H., 2014. CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide. *Clin Exp Allergy*, 44, 517-528.
- van der Werf, N., Redpath, S.A., Azuma, M., Yagita, H., Taylor, M.D., 2013. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. *PLoS Pathog*, 9, e1003215.
- Wang, R.X., Yu, C.R., Dambuza, I.M., Mahdi, R.M., Dolinska, M.B., Sergeev, Y.V., Wingfield, P.T., Kim, S.H., Egwuagu, C.E., 2014. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. *Nat Med*, 20, 633-641.

- Wilson, M.S., Taylor, M.D., O'Gorman, M.T., Balic, A., Barr, T.A., Filbey, K., Anderton, S.M., Maizels, R.M., 2010. Helminth-induced CD19⁺CD23^{hi} B cells modulate experimental allergic and autoimmune inflammation. *Eur J Immunol*, 40, 1682-1696.
- Xiao, S., Brooks, C.R., Zhu, C., Wu, C., Sweere, J.M., Petecka, S., Yeste, A., Quintana, F.J., Ichimura, T., Sobel, R.A., Bonventre, J.V., Kuchroo, V.K., 2012. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. *Proc Natl Acad Sci U S A* 109, 12105-12110.

Figure legends

Fig. 1. Schistosome-induced pulmonary B cells do not share phenotypical characteristics of classical regulatory B (Breg) cells. Mice were chronically (15 weeks) infected with 36-40 *Schistosoma mansoni* cercariae. Allergic sensitization was induced by two i.p. injections of ovalbumin (OVA)/alum 1 week apart and control mice received PBS. Seven days after the last injection, mice were challenged by OVA aerosol exposure on three consecutive days. Mice were sacrificed 24 h after the last challenge. The perfused lungs were minced, digested and the single cell suspension from 2-3 mice pooled. Next, B cells were purified using anti-CD19 MicroBeads and stained for different Breg cell-associated markers. (A) The fold change of percentage surface latency-associated peptide (LAP)-, CD25-, T cell immunoglobulin and mucin domain-1 (Tim-1)- and CD5-expressing B cells from uninfected- and infected/OVA mice over control (uninfected/PBS) are shown, representing a summary of 2-4 independent experiments ($n=11-17/\text{group}$). (B) Fold change of percentage and geometric mean fluorescence intensity (MFI) of CD23 expression over control (uninfected/PBS). Summary of four independent experiments ($n=14-17/\text{group}$). Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$, as tested by two-tailed unpaired Student's *t*-test.

Fig. 2. Pulmonary B cell-induced protection against allergic airway inflammation (AAI) during schistosomiasis is independent of Foxp3⁺ regulatory T (Treg) cells. Ovalbumin (OVA)-sensitized Dereg (DEpletion of REGulatory T cells) mice, which carry a

diphtheria toxin (DT) receptor-eGFP transgene under the control of an additional Foxp3 promoter, were treated with two PBS or DT (1 $\mu\text{g}/\text{mouse}$) i.p. injections in order to deplete the Foxp3⁺ Treg cells, 1 day before and 2 days after the adoptive transfer of 5 x 10⁶ CD19⁺ lung B cells. After 2 days, mice were challenged for three consecutive days and sacrificed 24 h after the last challenge. (A) The percentage of Foxp3⁺ CD25⁺ Treg cells in the lungs are shown, representing a summary of 1-2 independent experiments ($n=2-8/\text{group}$). (B) Fold change of bronchoalveolar lavage (BAL) eosinophil numbers over PBS-injected DEREK mice that did not receive B cell adoptive transfer. A summary of two independent experiments ($n=3-7/\text{group}$) is shown. Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: **** $P < 0.0001$, as tested by two-tailed unpaired Student's *t*-test (A) or # $P < 0.05$ as tested by One-way ANOVA following Tukey's multiple comparisons test (B). n.s., not significant.

Fig. 3. Schistosome-induced pulmonary B cells express elevated levels of CD86 ex vivo, and secrete less IL-10 after in vitro Toll-like receptor (TLR) ligation. Pulmonary B cells were isolated as described in Fig. 1. For both phenotypical characterization and co-culture, pulmonary B cells from 2-3 mice were pooled to obtain sufficient cell numbers. (A) Fold changes of geometric mean fluorescence intensity (MFI) expression of indicated antigens on B cells from uninfected/ovalbumin (OVA) and infected/OVA mice over control (uninfected/PBS). A summary of 2-4 independent experiments ($n=6-17/\text{group}$) is shown. (B) Uninfected/OVA and infected/OVA B cells were stimulated with supplemented RPMI medium (Med), schistosomal egg antigen (SEA, 20 $\mu\text{g}/\text{ml}$), lipopolysaccharide (LPS, 100 ng/ml) or CpG-ODN 1826 (5 $\mu\text{g}/\text{ml}$) for 5 days to

determine the presence of IL-10 and IL-6 in the supernatant. Data represents a summary of 2-4 independent experiments ($n=4-12/\text{group}$). Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: $*P < 0.05$, $**P < 0.01$, $****P < 0.0001$, as tested by two-tailed unpaired Student's t -test.

Fig. 4. Schistosome-induced pulmonary B cells have an impaired capacity to induce Th2 cytokine secretion in vitro. Pulmonary B cells were isolated as described in Fig. 1.

Pulmonary B cells, pooled from 2-3 mice per group were co-cultured at a 1:1 ratio with either naïve, ovalbumin (OVA)-peptide loaded OT-II CD4⁺ T cells (A) or naïve C57BL/6 CD4⁺ T cells (B-E). (A) B cells were loaded with OVA₁₇ peptide, washed and co-cultured at a 1:1 ratio with OVA-specific CD4⁺ OTII T cells in the presence of anti-CD28 (1 $\mu\text{g}/\text{ml}$) for 3 days. Intracellular cytokine staining for the Th2 cytokines IL-13, IL-4 and IL-10, Th1 cytokine IFN- γ and Th17 cytokine IL-17 cells was performed following phorbol 12-myristate 13-acetate (PMA)/Ionomycin and Brefeldin A stimulation for the last 4 h. Data are expressed as fold change over co-culture with control B cells (uninfected/PBS). A summary of 2-3 independent experiments ($n=6-12/\text{group}$) is shown. Results are expressed as mean \pm S.E.M. (B-E) B cells were co-cultured at a 1:1 ratio with naïve, CFSE-stained (0.5 μM CFSE, 15 min) C57BL/6 CD4⁺ T cells in the presence of anti-CD3/anti-CD28 (both (1 $\mu\text{g}/\text{ml}$) for 3 days. (B) The proliferation index was calculated within FlowJo. A summary of three independent experiments ($n=15-20/\text{group}$) is shown. (C) The mean fluorescence intensity (MFI) of the activation marker CD25 on T cells assessed by flow cytometry. (D) Fold changes of percentage IL-4, IL-13, IL-10, IL-17 and IFN- γ -producing T cells over control (B cells from uninfected/PBS mice). A

summary of four independent experiments ($n=17/\text{group}$) is shown. (E) Naïve C57BL/6 CD4⁺ T cells (1×10^5) were cultured at ratios of 1:1, 1:2 and 1:4 (B cell:T cell) with B cells from uninfected/OVA and infected/OVA mice. Bar graphs represent fold changes of percentage Th2 cytokines production (with uninfected/OVA 1:1 ratio set to 1). A summary of two independent experiments ($n=6-7/\text{group}$) is shown. (F, G) IL-5 and IL-13 measured by ELISA in supernatants of bronchoalveolar lavage (BAL) fluid (F) and OVA-restimulated mediastinal lymph node (medLN) cells (G) from recipient mice after adoptive transfer of either uninfected/OVA or infected/OVA B cells. Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, as tested by two-tailed unpaired Student's *t*-test. # $P < 0.05$, #### $P < 0.0001$, as tested by One-way ANOVA and Tukey's multiple comparisons test.

Fig. 5. The impaired capacity of schistosome-induced pulmonary B cells to induce Th2 cytokines is independent of IL-10 and TGF- β . In vitro co-cultures were performed as described in Fig. 4 in the presence of blocking anti-IL-10R, anti-TGF- β or isotype control antibodies. Bar graphs represent fold changes of IL-4 and IL-13 (with uninfected/ovalbumin (OVA) isotype set to 1). A summary of two independent experiments ($n=6-8/\text{group}$) is shown. Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: * $P < 0.05$, *** $P < 0.001$, **** $P < 0.0001$, as tested by two-tailed unpaired Student's *t*-test, and # $P < 0.05$ as tested by One-way ANOVA following Dunnett's multiple comparisons test.

Supplementary Figure legends

Supplementary Fig. S1. Gating strategy and representative flow cytometry plots, relating to Fig. 1. (A) Percentage of latency-associated peptide (LAP⁺), CD25⁺, T cell immunoglobulin and mucin domain-1 (Tim-1⁺) and CD23⁺ pulmonary B cells, as well as mean fluorescence intensity (MFI) of CD23. (B) Percentage of CD5⁺ pulmonary B cells. OVA, ovalbumin; FMO, fluorescence minus one control.

Supplementary Fig. S2. Gating strategy and representative flow cytometry plots, relating to Fig. 3A. (A) Percentage of CD86⁺, MHCII⁺, and (B) PD-L1⁺ and PD-L2⁺ pulmonary B cells in addition to the mean fluorescence intensities (MFIs) presented in Fig. 3A. OVA, ovalbumin; FMO, fluorescence minus one control.

Supplementary Fig. S3. Pulmonary B cells were isolated as described in Fig. 1. Cells from 2-3 mice were pooled to obtain sufficient cell numbers. (A) Representative flow cytometry plots showing the expression of the plasma cell marker CD138 on pulmonary B cells. (B) Fold change of percentage CD138-expressing B cells from uninfected/ovalbumin (OVA) and infected/OVA mice over control (uninfected/PBS). A summary of three independent experiments ($n=11-14/\text{group}$) is shown. (C) Fold change of mRNA expression of the IL-35 subunits Ebi3 and IL-12p35 as analyzed by quantitative PCR using β -2-microglobulin as a reference gene and the $\Delta\Delta$ comparative threshold method. Data represent one experiment ($n=3-6/\text{group}$). Results are expressed as mean \pm S.E.M. Significant differences are indicated as follows: *** $P < 0.001$, as tested by

a two-tailed unpaired Student's *t*-test. FMO, fluorescence minus one control; LPS, lipopolysaccharide.

Supplementary Fig. S4. Gating strategy and representative flow cytometry plots (relating to Fig. 4), showing the expression of IL-4 and IL-13 by (A) C57BL/6 T cells after co-culture with pulmonary B cells in the presence of anti-CD3 and anti-CD28, or (B) OTII T cells after co-culture with ovalbumin (OVA)₁₇ peptide-loaded pulmonary B cells in the presence of anti-CD28. FMO, fluorescence minus one control.